Lansforsakringar Fondforvaltning AB publ Purchases 3,853 Shares of Zoetis Inc. $ZTS

Key Points

• Lansforsakringar Fondforvaltning AB increased its stake in Zoetis Inc. by 1.1%, owning a total of 354,825 shares valued at approximately $58.4 million as of the latest SEC filing.
• Zoetis recently reported earnings of $1.76 per share, exceeding expectations, with quarterly revenue reaching $2.46 billion, a year-over-year increase of 4.2%.
• The company has faced mixed ratings from analysts, with recent reports lowering some price targets, while others maintain a positive outlook on Zoetis, reflected in an average rating of "Moderate Buy."

Lansforsakringar Fondforvaltning AB publ lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 354,825 shares of the company's stock after buying an additional 3,853 shares during the period. Lansforsakringar Fondforvaltning AB publ owned about 0.08% of Zoetis worth $58,422,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ZTS. Navigoe LLC acquired a new stake in Zoetis in the 4th quarter valued at about $30,000. Cornerstone Planning Group LLC lifted its position in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after acquiring an additional 120 shares during the last quarter. Sound Income Strategies LLC lifted its position in Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after acquiring an additional 164 shares during the last quarter. Finally, Bfsg LLC lifted its position in Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after acquiring an additional 252 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS traded up $1.66 during trading hours on Monday, hitting $156.45. The stock had a trading volume of 1,534,551 shares, compared to its average volume of 3,151,983. The company has a 50 day simple moving average of $153.51 and a two-hundred day simple moving average of $157.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The firm has a market capitalization of $69.34 billion, a price-to-earnings ratio of 26.93, a P/E/G ratio of 2.51 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.18% of the company's stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent analyst reports. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler boosted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Finally, UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.